Out-of-pocket expenditures and financial risks associated with treatment of vaccine-preventable diseases in Ethiopia: A cross-sectional costing analysis.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
03 2023
Historique:
received: 27 07 2022
accepted: 10 02 2023
entrez: 10 3 2023
pubmed: 11 3 2023
medline: 15 3 2023
Statut: epublish

Résumé

Vaccine-preventable diseases (VPDs) remain major causes of morbidity and mortality in low- and middle-income countries (LMICs). Universal access to vaccination, besides improved health outcomes, would substantially reduce VPD-related out-of-pocket (OOP) expenditures and associated financial risks. This paper aims to estimate the extent of OOP expenditures and the magnitude of the associated catastrophic health expenditures (CHEs) for selected VPDs in Ethiopia. We conducted a cross-sectional costing analysis, from the household (patient) perspective, of care-seeking for VPDs in children aged under 5 years for pneumonia, diarrhea, measles, and pertussis, and in children aged under 15 years for meningitis. Data on OOP direct medical and nonmedical expenditures (2021 USD) and household consumption expenditures were collected from 995 households (1 child per household) in 54 health facilities nationwide between May 1 and July 31, 2021. We used descriptive statistics to measure the main outcomes: magnitude of OOP expenditures, along with the associated CHE within households. Drivers of CHE were assessed using a logistic regression model. The mean OOP expenditures per disease episode for outpatient care for diarrhea, pneumonia, pertussis, and measles were $5·6 (95% confidence interval (CI): $4·3, 6·8), $7·8 ($5·3, 10·3), $9·0 ($6·4, 11·6), and $7·4 ($3·0, 11·9), respectively. The mean OOP expenditures were higher for inpatient care, ranging from $40·6 (95% CI: $12·9, 68·3) for severe measles to $101·7 ($88·5, 114·8) for meningitis. Direct medical expenditures, particularly drug and supply expenses, were the major cost drivers. Among those who sought inpatient care (345 households), about 13·3% suffered CHE, at a 10% threshold of annual consumption expenditures. The type of facility visited, receiving inpatient care, and wealth were significant predictors of CHE (p-value < 0·001) while adjusting for area of residence (urban/rural), diagnosis, age of respondent, and household family size. Limitations include inadequate number of measles and pertussis cases. The OOP expenditures induced by VPDs are substantial in Ethiopia and disproportionately impact those with low income and those requiring inpatient care. Expanding equitable access to vaccines cannot be overemphasized, for both health and economic reasons. Such realization requires the government's commitment toward increasing and sustaining vaccine financing in Ethiopia.

Sections du résumé

BACKGROUND
Vaccine-preventable diseases (VPDs) remain major causes of morbidity and mortality in low- and middle-income countries (LMICs). Universal access to vaccination, besides improved health outcomes, would substantially reduce VPD-related out-of-pocket (OOP) expenditures and associated financial risks. This paper aims to estimate the extent of OOP expenditures and the magnitude of the associated catastrophic health expenditures (CHEs) for selected VPDs in Ethiopia.
METHODS AND FINDINGS
We conducted a cross-sectional costing analysis, from the household (patient) perspective, of care-seeking for VPDs in children aged under 5 years for pneumonia, diarrhea, measles, and pertussis, and in children aged under 15 years for meningitis. Data on OOP direct medical and nonmedical expenditures (2021 USD) and household consumption expenditures were collected from 995 households (1 child per household) in 54 health facilities nationwide between May 1 and July 31, 2021. We used descriptive statistics to measure the main outcomes: magnitude of OOP expenditures, along with the associated CHE within households. Drivers of CHE were assessed using a logistic regression model. The mean OOP expenditures per disease episode for outpatient care for diarrhea, pneumonia, pertussis, and measles were $5·6 (95% confidence interval (CI): $4·3, 6·8), $7·8 ($5·3, 10·3), $9·0 ($6·4, 11·6), and $7·4 ($3·0, 11·9), respectively. The mean OOP expenditures were higher for inpatient care, ranging from $40·6 (95% CI: $12·9, 68·3) for severe measles to $101·7 ($88·5, 114·8) for meningitis. Direct medical expenditures, particularly drug and supply expenses, were the major cost drivers. Among those who sought inpatient care (345 households), about 13·3% suffered CHE, at a 10% threshold of annual consumption expenditures. The type of facility visited, receiving inpatient care, and wealth were significant predictors of CHE (p-value < 0·001) while adjusting for area of residence (urban/rural), diagnosis, age of respondent, and household family size. Limitations include inadequate number of measles and pertussis cases.
CONCLUSIONS
The OOP expenditures induced by VPDs are substantial in Ethiopia and disproportionately impact those with low income and those requiring inpatient care. Expanding equitable access to vaccines cannot be overemphasized, for both health and economic reasons. Such realization requires the government's commitment toward increasing and sustaining vaccine financing in Ethiopia.

Identifiants

pubmed: 36897870
doi: 10.1371/journal.pmed.1004198
pii: PMEDICINE-D-22-02567
pmc: PMC10004560
doi:

Banques de données

figshare
['10.6084/m9.figshare.20425434']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1004198

Informations de copyright

Copyright: © 2023 Memirie et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Value Health. 2021 Jan;24(1):78-85
pubmed: 33431157
Health Policy Plan. 2020 Oct 1;35(8):1003-1010
pubmed: 32772112
Lancet Glob Health. 2018 Feb;6(2):e169-e179
pubmed: 29248367
Health Econ. 2003 Nov;12(11):921-34
pubmed: 14601155
Trop Med Int Health. 2009 Oct;14(10):1315-22
pubmed: 19719464
J Health Popul Nutr. 2010 Oct;28(5):436-42
pubmed: 20941894
Health Aff (Millwood). 2018 Feb;37(2):316-324
pubmed: 29401021
Bull World Health Organ. 2010 Jun;88(6):402
pubmed: 20539847
Nat Med. 2021 Mar;27(3):380-387
pubmed: 33723458
Vaccine X. 2021 Apr 02;8:100095
pubmed: 34036262
BMC Health Serv Res. 2023 Jan 23;23(1):67
pubmed: 36683041
Pan Afr Med J. 2020 Nov 16;37(Suppl 1):36
pubmed: 33456660
Pan Afr Med J. 2017 Jun 21;27(Suppl 3):12
pubmed: 29296147
Cost Eff Resour Alloc. 2009 Oct 21;7:16
pubmed: 19845966
Health Aff (Millwood). 2009 Jul-Aug;28(4):1056-66
pubmed: 19597204
BMJ Glob Health. 2017 Jan 18;2(1):e000166
pubmed: 28589003
Clin Infect Dis. 2012 Dec;55 Suppl 4:S317-26
pubmed: 23169944
BMJ Glob Health. 2017 Jun 02;2(2):e000280
pubmed: 29242752
Vaccine. 2013 Apr 18;31 Suppl 2:B5-31
pubmed: 23734366
Elife. 2021 Jul 13;10:
pubmed: 34253291
Lancet. 2021 Jan 30;397(10272):398-408
pubmed: 33516338
Health Aff (Millwood). 2020 Aug;39(8):1343-1353
pubmed: 32744930
Vaccine. 2012 Dec 17;31(1):96-108
pubmed: 23142307

Auteurs

Solomon Tessema Memirie (ST)

Addis Center for Ethics and Priority Setting, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Mieraf Taddesse Tolla (MT)

Addis Center for Ethics and Priority Setting, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

Eva Rumpler (E)

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Ryoko Sato (R)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Sarah Bolongaita (S)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Yohannes Lakew Tefera (YL)

Ministry of Heath of Ethiopia, Addis Ababa, Ethiopia.

Latera Tesfaye (L)

National Data Management Center for Health, Ethiopian Public Health Institute, Addis Ababa, Ethiopia.

Meseret Zelalem Tadesse (MZ)

Ministry of Heath of Ethiopia, Addis Ababa, Ethiopia.

Fentabil Getnet (F)

National Data Management Center for Health, Ethiopian Public Health Institute, Addis Ababa, Ethiopia.

Tewodaj Mengistu (T)

Gavi, the Vaccine Alliance, Geneva, Switzerland.

Stéphane Verguet (S)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH